Clin2
NCT07195825Possibly a fitRecruiting

Gene therapy BBM-P002 for Parkinson's disease safety trial

PD

Part of Brain & nervous system clinical trials.

This trial tests a new gene therapy called BBM-P002 for Parkinson's disease. It aims to see if the treatment is safe and tolerable, and may help people with moderate to advanced Parkinson's who have had the condition for at least 5 years.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
18 people
Ages
40 years to 70 years
Study type
Interventional

Who can take part

  • You have had Parkinson's disease for at least 5 years.
  • You are on a stable, regular dose of medications like levodopa.
  • You agree to delay any brain surgery for Parkinson's during the study.
  • You agree to not get any vaccines during the main part of the study.
  • If you are able to become pregnant, you agree to use reliable birth control for at least 52 weeks after the dose.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07085195Not yet recruiting· Early Phase 1
Gene therapy for Parkinson's disease safety study

This study tests a new gene therapy (chemogenetics) to see if it is safe and how well it works for people with Parkinson's disease. The treatment involves a one-time infusion of a modified virus into the brain to help control movement symptoms.

Shanghai
NCT07157345Recruiting· Phase 1
Testing PDR-001 for Parkinson's Disease

This trial tests a new drug, PDR-001, to see if it can safely remove harmful proteins from the brain in people with early Parkinson's disease. It may help slow down the disease.

Shanghai, Shanghai Municipality
NCT05882487Not yet recruiting· Early Phase 1
Study drug KL002 for advanced Parkinson’s disease

This early-phase trial tests how safe and potentially effective KL002 is for people with advanced Parkinson’s disease. It may help reduce Parkinson’s movement symptoms, but the main early goal is safety.

Hangzhou, Zhejiang
NCT07215403Not yet recruiting· Phase 2
Gene therapy study for advanced Parkinson's disease

This trial tests a gene therapy for people with advanced Parkinson's disease (at least 10 years since diagnosis). It uses a special infusion to deliver treatment directly into the brain. The goal is to see if it can improve motor symptoms.

Cleveland, Ohio
NCT06732180Recruiting· Phase 1
Testing a new drug (GT-02287) for Parkinson's disease

This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.

Darlinghurst, New South Wales
NCT07718659Not yet recruiting· Phase 1
Gene therapy for Parkinson's disease

This trial tests a new gene therapy called ZR001 for people with Parkinson's disease. It involves a one-time surgery to inject the therapy into the brain, and researchers want to see if it's safe and can help improve movement symptoms.

Jinan, Shandong

Hear when a new PD trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.